Module

Impact of Nonalcoholic Fatty Liver Disease on Hepatitis C

Source: Hepatitis Annual Update 2004

Impact of Nonalcoholic Fatty Liver Disease on Hepatitis C


Program Director: John P. Phair, MD

Faculty:

  • Brent A. Tetri, MD

CME CREDIT INFORMATION

Release Date: 09/10/04

Expiration Date: 09/09/05


Physicians: maximum of 0.5 AMA PRA Category 1 Credit(s)™

Status: Please log in to view status


Learning Objectives

Upon completion of this activity, participants should be able to:

  • Define fatty liver syndromes.

  • Discuss the relationship between diabetes and hepatitis C.

  • Discuss the relationship between steatosis and hepatitis C virus (HCV) in terms of effect of obesity on the natural history of HCV liver disease, and the relationship between steatosis and treatment of hepatitis C, including weight-based dosing adjustments.


Content includes:

  • Steatosis and Hepatitis C
  • Steatosis as a Modifier of Treatment Response
  • Clinical Management
  • Diagnosis: Measuring Insulin Resistance
  • Therapeutic Approaches
  • Weight loss
  • Drug Therapy
  • Pathogenesis
  • Insulin Resistance as a Cause of Fatty Liver
  • Hepatitis C as a Cause of Fatty Liver
Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.

Jointly sponsored by Northwestern University’s Feinberg School of Medicine and Clinical Care Options, LLC.

Educational grant provided by:

Educational grants support only the CME-certified components of this program.